Market to Grow by 12.1% to Reach $6.97 Billion this Year - Investment Opportunities to 2029
DUBLIN — The 'Canada Diabetes Devices and Therapeutics Market Investment Opportunities – Q2 2025 Update' report has been added to ResearchAndMarkets.com's offering.
Article content
The diabetes market in Canada is expected to grow by 12.1% on annual basis to reach US$6.97 billion in 2025. The diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 12.9%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 10.0% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 6.22 billion to approximately USD 11.37 billion.
Article content
This report provides a detailed data-centric analysis of the diabetes industry in Canada, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics.
Article content
The diabetes devices and therapeutics market in Canada comprises established multinational firms and emerging domestic players. A structured healthcare system with defined reimbursement pathways supports traditional and digital solutions. The Canadian diabetes devices and therapeutics market is characterized by a blend of multinational leaders and emerging technology-driven entrants. Recent strategic partnerships, mergers, and acquisitions indicate a move toward more integrated care solutions. In the coming years, competitive dynamics are expected to intensify, driven by consolidation and a focused shift toward digital integration and regulatory compliance.
Article content
The Canadian market is experiencing significant shifts, with increased CGM adoption, digital integration, advanced therapeutic systems, and evolving regulatory support. These trends will intensify over the next 2-4 years, shaping clinical practices and reimbursement structures across provincial healthcare systems.
Article content
Expand Continuous Glucose Monitoring Usage
Article content
Canadian healthcare systems are broadening the use of continuous glucose monitoring (CGM) devices across several provinces. Provincial pilot programs in regions such as Ontario and British Columbia are incorporating CGM into routine diabetes care.
Adjustments in provincial reimbursement policies and recent clinical studies from Canadian health agencies support wider CGM use. Recent publications have highlighted a shift in clinical practice toward data-driven patient monitoring.
The adoption of CGM is expected to intensify as more provinces expand coverage and integrate real-time data into care protocols. Enhanced patient monitoring may improve diabetes management outcomes over the medium term.
Article content
Digital health platforms that support remote monitoring and telemedicine are increasingly integrated into diabetes management in Canada. Several regional healthcare systems have initiated digital dashboards to consolidate patient data for clinical decision-making.
Government initiatives to improve telehealth services and recent shifts in healthcare delivery models are driving digital integration. Recent publications underscore provincial health ministries' investments in digital infrastructure.
The integration of digital tools is projected to grow, supporting real-time care adjustments and enhanced data sharing among providers. This trend is expected to intensify as digital health reshapes chronic disease management.
Article content
Advance Therapeutic Delivery Systems
Article content
Advanced therapeutic devices such as smart insulin pens and connected insulin pumps are being tested in clinical settings across Canada. Pilot programs in select provinces have assessed these devices for precise dosing and improved treatment adherence.
Recent technological improvements and research findings from Canadian institutions support the development of these systems. Funding and innovation incentives from provincial health programs are fostering the introduction of these therapeutic tools.
Adoption will likely grow as clinical evidence and reimbursement models evolve, integrating these devices into standard practice. The trend is expected to intensify gradually, influencing treatment protocols in diabetes care.
Article content
Regulatory and Reimbursement Models
Article content
Regulatory bodies in Canada are updating guidelines and reimbursement policies to accommodate new diabetes devices and therapeutics. Recent policy documents have outlined pathways for including digital health and connected devices in public healthcare programs.
Broader cost-containment strategies and ongoing evaluations of digital health effectiveness drive regulatory adjustments. Publications from provincial health ministries and Health Canada provide context for these evolving frameworks.
Clearer regulatory and reimbursement models are anticipated to further support device integration and market expansion. These changes are expected to have a progressive impact, offering more defined channels for innovation in diabetes management.
Article content
Key Competitors and New Entrants
Article content
Several longstanding multinational companies hold significant market share. They offer a range of devices, from continuous monitoring systems to therapeutic delivery tools, and maintain strategic relationships with provincial healthcare agencies.
New market entrants, including technology-focused startups, are introducing digital health solutions that target remote monitoring and data integration. Recent publications indicate that pilot programs in provinces allow these entrants to demonstrate value.
Article content
Recent publications detail partnerships where established companies collaborate with digital health startups to enhance device connectivity and patient data analytics. Mergers and acquisitions have been noted as firms consolidate technical expertise and broaden their market offerings within the Canadian context.
These strategic developments reshape the market by promoting integrated care solutions and streamlined regulatory compliance. Collaborative efforts are aligning product innovation with provincial healthcare priorities.
Article content
Future Competitive Dynamics (2-4 Years)
Article content
The competitive landscape is expected to evolve as strategic partnerships and consolidation efforts deepen. Companies will likely increase investments in digital health integration, balancing established market leaders with nimble entrants.
Over the next 2-4 years, market consolidation and technology-driven innovation are anticipated to further define competitive positioning, with clear implications for patient management strategies.
Article content
Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices
Article content
Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices
Article content
Self-Monitoring Blood Glucose Devices
Continuous Blood Glucose Monitoring Devices
Test Strips
Lancets
Article content
Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices
Article content
Insulin Pumps
Insulin Pens
Insulin Syringes
Article content
Diabetes Devices and Therapeutics Market Share by Therapeutics
Article content
Oral Anti-Diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
Article content
Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs
Article content
Alpha-Glucosidase Inhibitors
DPP-4 Inhibitors
SGLT-2 Inhibitors
Article content
Diabetes Devices and Therapeutics Market Share by Insulin
Article content
Basal or Long-Acting
Bolus or Fast-Acting
Traditional Human Insulin Drugs
Insulin Biosimilars
Article content
Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs
Article content
GLP-1 Receptor Agonists
Amylin Analogue
Article content
Diabetes Devices and Therapeutics Market Share by Combination Drugs
Article content
Combination Insulin
Oral Combination
Article content
Diabetes Devices and Therapeutics Market Share by Route of Administration
Article content
Subcutaneous
Intravenous
Others
Article content
Diabetes Devices and Therapeutics Market Share by Type of Diabetes
Article content
Type 1 Diabetes
Type 2 Diabetes
Article content
Diabetes Devices and Therapeutics Market Share by Distribution Channels
Article content
Online Pharmacies
Hospital Pharmacies
Retail Pharmacies
Article content
Diabetes Devices and Therapeutics Market Share by End User
Article content
Hospitals
Diabetes Clinics
Homecare
Article content
Key Attributes:
Article content
Report Attribute Details
No. of Pages 50
Forecast Period 2025 – 2029
Estimated Market Value (USD) in 2025 $7.77 Billion
Forecasted Market Value (USD) by 2029 $11.37 Billion
Compound Annual Growth Rate 10.0%
Regions Covered Canada
Article content
For more information about this report visit https://www.researchandmarkets.com/r/5c4fnb About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
26 minutes ago
- Globe and Mail
Dexterra Announces Date of Q2 2025 Results and Conference Call
Toronto, Ontario--(Newsfile Corp. - July 15, 2025) - Dexterra Group Inc. (TSX: DXT) ("Dexterra") announces that it intends to release its Q2 2025 results on August 5, 2025 after market close and has scheduled a conference call and webcast to begin promptly at 8:30 a.m. Eastern Time on August 6, 2025. A presentation will be posted on the Dexterra website at on August 5, 2025 to be reviewed on the conference call. The conference call dial in number is 1-844-763-8274 A live webcast of the conference call will be accessible on Dexterra's website at by selecting the Q2 2025 Results webcast link. An archived recording of the conference call will be available approximately one hour after the completion of the call until September 6, 2025 by dialing 1-855-669-9658, passcode 3972185. About Dexterra Dexterra employs over 9,000 people, delivering a range of support services for the creation, management, and operation of infrastructure across Canada and the U.S. Powered by people, Dexterra brings best-in-class regional expertise to every challenge and delivers innovative solutions, giving clients confidence in their day-to-day operations. Activities include a comprehensive range of integrated facilities management services, industry-leading workforce accommodation solutions, and other support services for diverse clients in the public and private sectors. You can also visit our website at
Globe and Mail
26 minutes ago
- Globe and Mail
Bluesky Digital Assets Completes Second Tranche Closing of its Current Non-Brokered Private Placement Offering
Toronto, Ontario--(Newsfile Corp. - July 15, 2025) - Bluesky Digital Assets Corp., (CSE: BTC) (OTCQB: BTCWF), ("Bluesky" or the "Corporation") announced today the closing of the second tranche of the Non-Brokered Private Placement (the "Offering"). For the second tranche, the Corporation issued 1,200,000 Units at a price of $0.12 per Unit. Gross proceeds for the second tranche closing amounted to C$100,000. The Corporation has now raised a combined total of C$310,000 between the two tranches and has issued a combined total of 2,583,333 Units. All securities issued are subject to a statutory hold period of four months and one day from issuance. The Corporation paid a cash finder's fee of C$12,000 on the first tranche and issued 18,000 Finder's Warrants. No finders' fees were paid on the closing of the second tranche. The Corporation also announced that it is extending the closing of the Offering to August 15, 2025 (the " Closing Date"). As previously announced in the Corporation's July 8 th, 2015 press release, the Corporation has commenced a non-brokered private placement raise of up to 8,333,333 Units (" Unit") of the Corporation at a price of C$0.12 per Unit for aggregate gross proceeds of up to C$1,000,000 which will be offered for sale to purchasers resident in Canada (except Quebec) and/or other qualifying jurisdictions. Each Unit consists of one Common Share of the Corporation (" Common Share") and one Common Share Purchase Warrant (" Warrant"). Each full Warrant entitles its holder to acquire one additional Common Share at an exercise price of C$0.15 per Common Share for a period of 24 months following the closing of the Offering (" Closing Date"). Any Shares issued upon the exercise of the Warrants will be subject to a hold period of four months and one day from the date of issuance. The Corporation may pay registered persons a finder's fee comprised of 8% of the gross proceeds of the Offering in cash, and such number of non-transferable Finder's Warrants which equals 8% of the number of Units (the "Finder's Warrants"). Each Finder's Warrant shall entitle the holder to acquire one Common Share (the "Finder's Warrant Shares") at a price of $0.15 per Finder's Warrant Share for a period of two (2) years from the date of issuance. Other than being non-transferable, each Finder's Warrant shall otherwise be on the same terms as the Warrants. The Units, Shares, Warrants, Warrant Shares, Finder's Warrants, and Finder's Warrant Shares are collectively referred to herein as the "Securities". All Securities issued in connection with the Offering will be subject to a statutory hold period expiring four months and one day after the Closing. The securities issued under the Offering will not be registered under the United States Securities Act of 1933, as amended (the " Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Corporation intends to use the net proceeds from the Offering to further advance its AI development and online gaming endeavors and for General Working Capital Purposes. About Bluesky Digital Assets Corp. Bluesky Digital Assets Corp, has created a high value digital enterprise at the intersection of Artificial Intelligence, Blockchain and Web3 business solutions. Leveraging its success as an early adopter providing proprietary technology solutions, Bluesky has invested in its Roadmap. Bluesky's platform, BlueskyINTEL, is well positioned to leverage the current exponential growth of Artificial Intelligence ("AI") and Blockchain based technologies through a tightly focus built collaborative platform. This innovative web platform offering supports and better enables businesses to adopt and utilize these emerging and developing technologies. For more information please visit Bluesky at: or Please also follow us on Linkedin at: For further information, please contact: Mr. Ben Gelfand CEO & Director Bluesky Digital Assets Corp. T: (416) 363-3833 E: Mr. Frank Kordy Secretary & Director Bluesky Digital Assets Corp. T: (647) 466-4037 E: Forward-Looking Statements This news release may contain assumptions, estimates, and other forward-looking statements regarding future events. Such forward-looking statements involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements. Information set forth in this news release may involve forward-looking statements under applicable securities laws. The forward- looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document and the Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation. Although management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither CSE nor its Regulation Services Provider as that term is defined in the policies of the CSE accepts responsibility for the adequacy or accuracy of this release. We seek safe harbor. - 30 -
CBC
28 minutes ago
- CBC
Indigenous Services budget cuts?
Cutting billions of dollars from the federal Indigenous services budget could worsen the quality of essential services and spark lawsuits that would cost Ottawa more money long term, some advocates say.
